Search

Your search keyword '"Verier-Mine O"' showing total 45 results
Start Over Author "Verier-Mine O"
45 results on '"Verier-Mine O"'

1. Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement

Author

Borot, S., Benhamou, P.Y., Atlan, C., Bismuth, E., Bonnemaison, E., Catargi, B., Charpentier, G., Farret, A., Filhol, N., Franc, S., Gouet, D., Guerci, B., Guilhem, I., Guillot, C., Jeandidier, N., Joubert, M., Melki, V., Merlen, E., Penfornis, A., Picard, S., Renard, E., Reznik, Y., Riveline, J.P., Rudoni, S., Schaepelynck, P., Sola-Gazagnes, A., Tubiana-Rufi, N., Verier-Mine, O., and Hanaire, H.

Published
2018
Full Text
View/download PDF

2. Treating diabetes with islet transplantation: Lessons from the past decade in Lille

Author

Balavoine, A.S., Bresson, R., Bourdelle-Hego, M.F., Cazaubiel, M., Cordonnier, M., Delefosse, D., Dorey, F., Fayard, A., Fermon, C., Fontaine, P., Gillot, C., Haye, S., Le Guillou, A.C., Karrouz, W., Lemaire, C., Lepeut, M., Leroy, R., Mycinski, B., Parent, E., Siame, C., Sterkers, A., Torres, F., Verier-Mine, O., Verlet, E., Desailloud, R., Dürrbach, A., Godin, M., Lalau, J.D., Lukas-Croisier, C., Thervet, E., Toupance, O., Reznik, Y., Westeel, P.F., Vantyghem, M.-C., Defrance, F., Quintin, D., Leroy, C., Raverdi, V., Prévost, G., Caiazzo, R., Kerr-Conte, J., Glowacki, F., Hazzan, M., Noel, C., and Pattou, F.

Published
2014
Full Text
View/download PDF

3. Le diabète gestationnel: Référentiel élaboré par le Collège national des gynécologues et obstétriciens français (CNGOF) et par la Société francophone du diabète (SFD) – 2010

Author

Vambergu, Anne, Lepercq, J., Vayssiere, C., Boulot, P., Burdet, I., Criballet, G., Fau, C., Grandjean, H., Simeoni, U., Vambergue, A., Beucher, G., Burguet, A., Cosson, E., Deruelle, P., Galtier, F., Guedj, A.-M., Guyard-Boileau, B., Hieronimus, S., Jacqueminet, S., Jannot-Lamotte, M.-F., Kerlan, V., Laloi-Michelin, M., Le meaux, J.-P., Mitanchez, D., Thiebaugeorges, O., Verier-Mine, O., and Virally, M.

Published
2010
Full Text
View/download PDF

7. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: Contributions of the GERODIAB study

Author

Bauduceau, B, Blicklé, J-F, Bourdel-Marchasson, I, Constans, T, Doucet, J, Fagot-Campagna, A, Kaloustian, E, Lassmann-Vague, V, Lecomte, P, Tessier, D, Verny, C, Vischer, U, Affres, H, Alix, M, Archambeaud, F, Barrou, Z, Beau, P, Beltran, S, Benoit, C, Beressi, J-P, Bernachon, F, Berne, C, Berrut, G, Blaimont, A, Blickle, J-F, Boda-Buccino, M, Bohatier, J, Böhme, P, Bordier, L, Bouchou, K, Bouillet, B, Bouilloud, F, Bouix, R, Boulanger, E, Bourgon, C, Bourrinet, E, Brocker, P, Bruckert, I, Capet, C, Carette, C, Cariou, B, Carreau, A, Vaurie, C Chaillou, Chamouni, S, Ciangura, C, Collet-Gaudillat, C, Combes-Moukhovsky, M-E, Cordonnier, M, Cuperlier, A, Dambre, D, D'Avigneau, J, De Botton, P, Degros, V, Delamarre-Damier, F, Denat, S, Desbiez, F, Deumier, B, Dorey, F, Dresco, E, Drutel, A, De Saint Germain, E Du Rosel, Dubois-Laforgue, D, Duly-Bouhanick, B, Dupuy, O, Dusselier, L, Faucher-Kareche, S, Fendri, S, Fontaine, P, Galinat, S, Gentric, A, Gin, H, Glaise, F, Godeau, T, Gonzales, B, Got, I, Guerci, B, Guillausseau, P-J, Hadjadj, S, Hadjali, Y, Halbron, M, Halimi, S, Halter, C, Hanaire, H, Hardy, V, Hartemann-Heurtier, A, Haulot, J-P, Hequet, F, Issa-Sayegh, M, Jan, P, Jeandidier, N, Joseph-Henri, H, Julier, I, Kerlan, V, Kharitonnoff, T, Ladsous, M, Lahaxe, L, Lamaraud, M-P, Lassenne, E, Lecerf, J-M, Leroux, I, Lesven, S, Levy, M, Lopez, S, Makiza, F, Manckoundia, P, Pomeau, C Marquis, Mayaudon, H, Micheli, S, Mira, R, Monnier, F, Mosnier-Pudar, H, Neri, N, Normand, I, Paccalin, M, Pagu, C, Paris, D, Penfornis, A, Perie, J-L, Petit, J-M, Petit-Aubert, G, Pichot-Duclos, B, Pivois, L, Popelier, M, Poulingue, G, Priner, M, Quipourt, V, Rasamisoa, M, Richard, J-L, Rigalleau, V, Roudat, N, Sanz, C, Serot, J-M, Sifi, D, Sirvain, S, Slimani, A, Sonnet, E, Sosset, C, Soualah, A, Stroea, A, Tauveron, I, Timsit, J, Tschudnowsky, M, Vambergue, A, Verier-Mine, O, Virally, M, Bordier, L., Buysschaert, M., Bauduceau, B., Doucet, J., Verny, C., Lassmann Vague, V., and Le Floch, J.P.

Published
2015
Full Text
View/download PDF

8. Éducation à l’utilisation pratique et à l’interprétation de la Mesure Continue du Glucose : position d’experts français

Author

Hanaire, H., primary, Atlan, C., additional, Benhamou, P.-Y., additional, Bismuth, E., additional, Bonnemaison, E., additional, Borot, S., additional, Catargi, B., additional, Charpentier, G., additional, Farret, A., additional, Filhol, N., additional, Franc, S., additional, Gouet, D., additional, Guerci, B., additional, Guilhem, I., additional, Guillot, C., additional, Jeandidier, N., additional, Joubert, M., additional, Melki, V., additional, Merlen, E., additional, Penfornis, A., additional, Picard, S., additional, Renard, E., additional, Reznik, Y., additional, Riveline, J.-P., additional, Rudoni, S., additional, Schaepelynck, P., additional, Sola-Gazagnes, A., additional, Tubiana, N., additional, and Verier-Mine, O., additional

Published
2017
Full Text
View/download PDF

9. Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold

Author

Chaturvedi, Nish, Bandinelli, Simona, Mangili, Ruggero, Penno, Guiseppe, Rottiers, Raoul E., Fuller, John H., Karamanos, B., Kofinis, A., Petrou, K., Giorgino, R., Giorgino, F., Picca, G., Angarano, A., De Pergola, G., Ionescu-Tirgoviste, C., Coszma, A., Songini, M., Casu, A., Pedron, M., Fossarello, M., Ferriss, J. B., Grealy, G., Keefe, D. O., White, A., Cleary, P. E., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Kyostio-Renvall, T., Idzior-Walus, B., Sieradzki, J., Cyganek, K., Lemkes, H. H. P. J., Roest, C., Nunes-Correa, J., Rogado, M. C., Gardete-Correia, L., Cardoso, M. C., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Lattanzio, Rosangela, Galardi, G., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, D., Verier-Mine, O., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D’ Alessandro, V., Cagini, C., Navalesi, R., Penno, G., Bandinelli, S., Miccoli, R., Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Porta, M., Perin, P. Cavallo, Borra, M., Giunti, S., Papazoglou, N., Manes, Gianfranco, Muggeo, M., Iagulli, M., Irsigler, K., Abrahamian, H., Walford, S., Wardle, E. V., Sinclair, J., Hughes, S., Roglic, G., Metelko, Z., Resman, Z., Sjolie, A. -. K., Chaturvedi, N., Ferriss, B., Webb, D., Viberti, G. -. C., Swaminathan, R., Lumb, P., Collins, A., Sankaralingham, S., Aldington, S., Mortemore, T., and Lipinski, H.

Subjects
Albuminuria, Blood sugar control, Cardiovascular disease, Insulin resistance, Renal disease, Adolescent, Adult, Blood Glucose, Body Constitution, Cohort Studies, Diabetes Mellitus, Type 1, Differential Threshold, Disease Progression, Europe, Female, Follow-Up Studies, Humans, Incidence, Insulin Resistance, Male, Middle Aged, Prospective Studies, Reference Values, Risk Factors, Triglycerides, Nephrology, endocrine system diseases, urologic and male genital diseases, Gastroenterology, Waist–hip ratio, Proteinuria, Settore MED/30 - MALATTIE APPARATO VISIVO, female genital diseases and pregnancy complications, medicine.symptom, Type 1, medicine.medical_specialty, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Risk factor, Glycemic, Type 1 diabetes, business.industry, nutritional and metabolic diseases, medicine.disease, Endocrinology, Microalbuminuria, business
Abstract

Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold.BackgroundThe occurrence of microalbuminuria in type 1 diabetes is strongly predictive of renal and cardiovascular disease and is still likely to occur despite improvements in glycemic control. A better understanding of microalbuminuria is required to inform new interventions. We determined the incidence and risk factors for microalbuminuria [albumin excretion rate (AER) 20 to 200 μg/min] in the EURODIAB Prospective Complications Study.MethodsThis is a seven-year follow-up (between 1988 and 1991) of 1134 normoalbuminuric men and women (aged 15 to 60) with type 1 diabetes from 31 European centers. Risk factors and AER were measured centrally.ResultsThe incidence of microalbuminuria was 12.6% over 7.3 years. Independent baseline risk factors were HbA1c (7.1 vs. 6.2%, P = 0.0001) and AER (9.6 vs. 7.8 μg/min, P = 0.0001) and, independent of these, fasting triglyceride (0.99 vs. 0.88 mmol/L, P = 0.01), low-density lipoprotein cholesterol (3.5 vs. 3.2 mmol/L, P = 0.02), body mass index (24.0 vs. 23.4 kg/m2, P = 0.01), and waist to hip ratio (WHR; 0.85 vs. 0.83, P = 0.009). Triglyceride and WHR risk factors were nearly as strong as AER in predicting microalbuminuria (standardized regression effects of 1.3 for triglyceride and WHR and 1.5 for AER). Blood pressure at follow-up, but not at baseline, was also raised in those who progressed. There was no evidence of a threshold of HbA1c on microalbuminuria risk.ConclusionsThe incidence of microalbuminuria in patients with type 1 diabetes remains high, and there is no apparent glycemic threshold for it. Markers of insulin resistance, such as triglyceride and WHR, are strong risk factors. Systemic blood pressure is not raised prior to the onset of microalbuminuria.

Published
2001
Full Text
View/download PDF

12. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: Contributions of the GERODIAB study

Author

Bordier, L., primary, Buysschaert, M., additional, Bauduceau, B., additional, Doucet, J., additional, Verny, C., additional, Lassmann Vague, V., additional, Le Floch, J.P., additional, Bauduceau, B, additional, Blicklé, J-F, additional, Bourdel-Marchasson, I, additional, Constans, T, additional, Doucet, J, additional, Fagot-Campagna, A, additional, Kaloustian, E, additional, Lassmann-Vague, V, additional, Lecomte, P, additional, Tessier, D, additional, Verny, C, additional, Vischer, U, additional, Affres, H, additional, Alix, M, additional, Archambeaud, F, additional, Barrou, Z, additional, Beau, P, additional, Beltran, S, additional, Benoit, C, additional, Beressi, J-P, additional, Bernachon, F, additional, Berne, C, additional, Berrut, G, additional, Blaimont, A, additional, Blickle, J-F, additional, Boda-Buccino, M, additional, Bohatier, J, additional, Böhme, P, additional, Bordier, L, additional, Bouchou, K, additional, Bouillet, B, additional, Bouilloud, F, additional, Bouix, R, additional, Boulanger, E, additional, Bourgon, C, additional, Bourrinet, E, additional, Brocker, P, additional, Bruckert, I, additional, Capet, C, additional, Carette, C, additional, Cariou, B, additional, Carreau, A, additional, Vaurie, C Chaillou, additional, Chamouni, S, additional, Ciangura, C, additional, Collet-Gaudillat, C, additional, Combes-Moukhovsky, M-E, additional, Cordonnier, M, additional, Cuperlier, A, additional, Dambre, D, additional, D'Avigneau, J, additional, De Botton, P, additional, Degros, V, additional, Delamarre-Damier, F, additional, Denat, S, additional, Desbiez, F, additional, Deumier, B, additional, Dorey, F, additional, Dresco, E, additional, Drutel, A, additional, De Saint Germain, E Du Rosel, additional, Dubois-Laforgue, D, additional, Duly-Bouhanick, B, additional, Dupuy, O, additional, Dusselier, L, additional, Faucher-Kareche, S, additional, Fendri, S, additional, Fontaine, P, additional, Galinat, S, additional, Gentric, A, additional, Gin, H, additional, Glaise, F, additional, Godeau, T, additional, Gonzales, B, additional, Got, I, additional, Guerci, B, additional, Guillausseau, P-J, additional, Hadjadj, S, additional, Hadjali, Y, additional, Halbron, M, additional, Halimi, S, additional, Halter, C, additional, Hanaire, H, additional, Hardy, V, additional, Hartemann-Heurtier, A, additional, Haulot, J-P, additional, Hequet, F, additional, Issa-Sayegh, M, additional, Jan, P, additional, Jeandidier, N, additional, Joseph-Henri, H, additional, Julier, I, additional, Kerlan, V, additional, Kharitonnoff, T, additional, Ladsous, M, additional, Lahaxe, L, additional, Lamaraud, M-P, additional, Lassenne, E, additional, Lecerf, J-M, additional, Leroux, I, additional, Lesven, S, additional, Levy, M, additional, Lopez, S, additional, Makiza, F, additional, Manckoundia, P, additional, Pomeau, C Marquis, additional, Mayaudon, H, additional, Micheli, S, additional, Mira, R, additional, Monnier, F, additional, Mosnier-Pudar, H, additional, Neri, N, additional, Normand, I, additional, Paccalin, M, additional, Pagu, C, additional, Paris, D, additional, Penfornis, A, additional, Perie, J-L, additional, Petit, J-M, additional, Petit-Aubert, G, additional, Pichot-Duclos, B, additional, Pivois, L, additional, Popelier, M, additional, Poulingue, G, additional, Priner, M, additional, Quipourt, V, additional, Rasamisoa, M, additional, Richard, J-L, additional, Rigalleau, V, additional, Roudat, N, additional, Sanz, C, additional, Serot, J-M, additional, Sifi, D, additional, Sirvain, S, additional, Slimani, A, additional, Sonnet, E, additional, Sosset, C, additional, Soualah, A, additional, Stroea, A, additional, Tauveron, I, additional, Timsit, J, additional, Tschudnowsky, M, additional, Vambergue, A, additional, Verier-Mine, O, additional, and Virally, M, additional

Published
2015
Full Text
View/download PDF

14. Concerns over the consequences of regional disparities for elderly French type 2 diabetes patients in the Gerodiab study

Author

Le Floch, J.-P., primary, Doucet, J., additional, Bauduceau, B., additional, Verny, C., additional, Bauduceau, B, additional, Blicklé, J-F, additional, Bourdel-Marchasson, I, additional, Constans, T, additional, Doucet, J, additional, Fagot-Campagna, A, additional, Kaloustian, E, additional, Lassmann-Vague, V, additional, Lecomte, P, additional, Tessier, D, additional, Verny, C, additional, Vischer, U, additional, Affres, H, additional, Alix, M, additional, Archambeaud, F, additional, Barrou, Z, additional, Beau, P, additional, Beltran, S, additional, Benoit, C, additional, Beressi, J-P, additional, Bernachon, F, additional, Berne, C, additional, Berrut, G, additional, Blaimont, A, additional, Blickle, J-F, additional, Boda-Buccino, M, additional, Bohatier, J, additional, Böhme, P, additional, Bordier, L, additional, Bouchou, K, additional, Bouillet, B, additional, Bouilloud, F, additional, Bouix, R, additional, Boulanger, E, additional, Bourgon, C, additional, Bourrinet, E, additional, Brocker, P, additional, Bruckert, I, additional, Capet, C, additional, Carette, C, additional, Cariou, B, additional, Carreau, A, additional, Vaurie, C Chaillou, additional, Chamouni, S, additional, Ciangura, C, additional, Collet-Gaudillat, C, additional, Combes-Moukhovsky, M-E, additional, Cordonnier, M, additional, Cuperlier, A, additional, Dambre, D, additional, D'Avigneau, J, additional, De Botton, P, additional, Degros, V, additional, Delamarre-Damier, F, additional, Denat, S, additional, Desbiez, F, additional, Deumier, B, additional, Dorey, F, additional, Dresco, E, additional, Drutel, A, additional, De Saint Germain, E Du Rosel, additional, Dubois-Laforgue, D, additional, Duly-Bouhanick, B, additional, Dupuy, O, additional, Dusselier, L, additional, Faucher-Kareche, S, additional, Fendri, S, additional, Fontaine, P, additional, Galinat, S, additional, Gentric, A, additional, Gin, H, additional, Glaise, F, additional, Godeau, T, additional, Gonzales, B, additional, Got, I, additional, Guerci, B, additional, Guillausseau, P-J, additional, Hadjadj, S, additional, Hadjali, Y, additional, Halbron, M, additional, Halimi, S, additional, Halter, C, additional, Hanaire, H, additional, Hardy, V, additional, Hartemann-Heurtier, A, additional, Haulot, J-P, additional, Hequet, F, additional, Issa-Sayegh, M, additional, Jan, P, additional, Jeandidier, N, additional, Joseph-Henri, H, additional, Julier, I, additional, Kerlan, V, additional, Kharitonnoff, T, additional, Ladsous, M, additional, Lahaxe, L, additional, Lamaraud, M-P, additional, Lassenne, E, additional, Lecerf, J-M, additional, Leroux, I, additional, Lesven, S, additional, Levy, M, additional, Lopez, S, additional, Makiza, F, additional, Manckoundia, P, additional, Pomeau, C Marquis, additional, Mayaudon, H, additional, Micheli, S, additional, Mira, R, additional, Monnier, F, additional, Mosnier-Pudar, H, additional, Neri, N, additional, Normand, I, additional, Paccalin, M, additional, Pagu, C, additional, Paris, D, additional, Penfornis, A, additional, Perie, J-L, additional, Petit, J-M, additional, Petit-Aubert, G, additional, Pichot-Duclos, B, additional, Pivois, L, additional, Popelier, M, additional, Poulingue, G, additional, Priner, M, additional, Quipourt, V, additional, Rasamisoa, M, additional, Richard, J-L, additional, Rigalleau, V, additional, Roudat, N, additional, Sanz, C, additional, Serot, J-M, additional, Sifi, D, additional, Sirvain, S, additional, Slimani, A, additional, Sonnet, E, additional, Sosset, C, additional, Soualah, A, additional, Stroea, A, additional, Tauveron, I, additional, Timsit, J, additional, Tschudnowsky, M, additional, Vambergue, A, additional, Verier-Mine, O, additional, and Virally, M, additional

Published
2014
Full Text
View/download PDF

15. Les mutations SOX10 responsables de l’association des syndromes de Kallmann et Waardenburg

Author

Pingault, V., primary, Bodereau, V., additional, Baral, V., additional, Marcos, S., additional, Watanabe, Y., additional, Chaoui, A., additional, Fouveaut, C., additional, Leroy, C., additional, Verier-Mine, O., additional, Francannet, C., additional, Dupin-Deguine, D., additional, Archambeaud, F., additional, Kurtz, F., additional, Young, J., additional, Bertherat, J., additional, Marlin, S., additional, Goossens, M., additional, Hardelin, J.P., additional, Dode, C., additional, and Bondurand, N., additional

Published
2013
Full Text
View/download PDF

16. PO32 Concentrations sériques de stéroïdes sexuels, gène de l’aromatase (CYP19A1) et risques cardiovasculaire et rénal chez des sujets diabétiques de type 2

Author

Saulnier, P.-J., primary, Gourdy, P., additional, Gallois, Y., additional, Ragot, S., additional, Charpentier, G., additional, Guilloteau, G., additional, Guerci, B., additional, Roussel, R., additional, Halimi, J.-M., additional, Dupuy, O., additional, Verier-Mine, O., additional, Rachedi, F., additional, Sechet, A., additional, Marechaud, R., additional, Marre, M., additional, and Hadjadj, S., additional

Published
2013
Full Text
View/download PDF

18. PO25 Concentrations sériques de stéroïdes sexuels, gène de l’aromatase et néphropathie diabétique.

Author

Saulnier, P.J., primary, Ragot, S., additional, Gourdy, P., additional, Lecomte, P., additional, Guilloteau, G., additional, Charpentier, G., additional, Guerci, B., additional, Rachedi, F., additional, Dupuy, O., additional, Verier-Mine, O., additional, Roussel, R., additional, Bonnet, S., additional, Sechet, A., additional, Marre, M., additional, and Hadjadj, S., additional

Published
2012
Full Text
View/download PDF

23. Le diabète gestationnel

Author

Vambergu, Anne, primary, Lepercq, J., additional, Vayssiere, C., additional, Boulot, P., additional, Burdet, I., additional, Criballet, G., additional, Fau, C., additional, Grandjean, H., additional, Simeoni, U., additional, Vambergue, A., additional, Beucher, G., additional, Burguet, A., additional, Cosson, E., additional, Deruelle, P., additional, Galtier, F., additional, Guedj, A.-M., additional, Guyard-Boileau, B., additional, Hieronimus, S., additional, Jacqueminet, S., additional, Jannot-Lamotte, M.-F., additional, Kerlan, V., additional, Laloi-Michelin, M., additional, Le meaux, J.-P., additional, Mitanchez, D., additional, Thiebaugeorges, O., additional, Verier-Mine, O., additional, and Virally, M., additional

Published
2010
Full Text
View/download PDF

25. P11 Campagne de dépistage de la microalbuminurie (MA) et des facteurs de risque (FDR) cardio-vasculaire (CV) dans la région Nord-Pas-de-Calais (NPdC)

Author

Lemaire, C., primary, Paix, Y., additional, Lepeut, M., additional, Verier Mine, O., additional, Escoufflaire, N., additional, Bresson, R., additional, Coliche, V., additional, Verlet, E., additional, Tetar, I., additional, Leblanc, N., additional, Lenne, X., additional, and Vambergue, A., additional

Published
2009
Full Text
View/download PDF

31. Concerns over the consequences of regional disparities for elderly French type 2 diabetes patients in the Gerodiab study

Author

Bauduceau, B, Blicklé, J-F, Bourdel-Marchasson, I, Constans, T, Doucet, J, Fagot-Campagna, A, Kaloustian, E, Lassmann-Vague, V, Lecomte, P, Tessier, D, Verny, C, Vischer, U, Affres, H, Alix, M, Archambeaud, F, Barrou, Z, Beau, P, Beltran, S, Benoit, C, Beressi, J-P, Bernachon, F, Berne, C, Berrut, G, Blaimont, A, Blickle, J-F, Boda-Buccino, M, Bohatier, J, Böhme, P, Bordier, L, Bouchou, K, Bouillet, B, Bouilloud, F, Bouix, R, Boulanger, E, Bourgon, C, Bourrinet, E, Brocker, P, Bruckert, I, Capet, C, Carette, C, Cariou, B, Carreau, A, Vaurie, C Chaillou, Chamouni, S, Ciangura, C, Collet-Gaudillat, C, Combes-Moukhovsky, M-E, Cordonnier, M, Cuperlier, A, Dambre, D, D'Avigneau, J, De Botton, P, Degros, V, Delamarre-Damier, F, Denat, S, Desbiez, F, Deumier, B, Dorey, F, Dresco, E, Drutel, A, De Saint Germain, E Du Rosel, Dubois-Laforgue, D, Duly-Bouhanick, B, Dupuy, O, Dusselier, L, Faucher-Kareche, S, Fendri, S, Fontaine, P, Galinat, S, Gentric, A, Gin, H, Glaise, F, Godeau, T, Gonzales, B, Got, I, Guerci, B, Guillausseau, P-J, Hadjadj, S, Hadjali, Y, Halbron, M, Halimi, S, Halter, C, Hanaire, H, Hardy, V, Hartemann-Heurtier, A, Haulot, J-P, Hequet, F, Issa-Sayegh, M, Jan, P, Jeandidier, N, Joseph-Henri, H, Julier, I, Kerlan, V, Kharitonnoff, T, Ladsous, M, Lahaxe, L, Lamaraud, M-P, Lassenne, E, Lecerf, J-M, Leroux, I, Lesven, S, Levy, M, Lopez, S, Makiza, F, Manckoundia, P, Pomeau, C Marquis, Mayaudon, H, Micheli, S, Mira, R, Monnier, F, Mosnier-Pudar, H, Neri, N, Normand, I, Paccalin, M, Pagu, C, Paris, D, Penfornis, A, Perie, J-L, Petit, J-M, Petit-Aubert, G, Pichot-Duclos, B, Pivois, L, Popelier, M, Poulingue, G, Priner, M, Quipourt, V, Rasamisoa, M, Richard, J-L, Rigalleau, V, Roudat, N, Sanz, C, Serot, J-M, Sifi, D, Sirvain, S, Slimani, A, Sonnet, E, Sosset, C, Soualah, A, Stroea, A, Tauveron, I, Timsit, J, Tschudnowsky, M, Vambergue, A, Verier-Mine, O, Virally, M, Le Floch, J.-P., Doucet, J., Bauduceau, B., and Verny, C.

Published
2014
Full Text
View/download PDF

36. [Selective control of different hypophysial secretions by long-lasting pharmacodynamic agents. Analogs of somatostatin and LHRH and long-lasting bromocriptine]

Author

Fossati P, DIDIER DEWAILLY, and Verier-Mine O

Subjects
Gonadotropin-Releasing Hormone, Structure-Activity Relationship, Humans, Secretory Rate, Somatostatin, Bromocriptine, Prolactin
Abstract

The biological activity of the natural somatostatin can be quantitatively and qualitatively altered by the substitution and/or the exclusion of some of its amino-acids. The most used synthetic analog, SMS 201-995, has a potent inhibiting effect on GH secretion, but is less effective on insulin and glucagon secretions. It is mainly used in Endocrinology for the treatment of acromegaly. It is also useful for inhibiting the inappropriate TSH secretion from a thyrotroph adenoma. The LH-RH agonists ast essentially by desensitizing the gonadotroph from the endogenous LH-RH. By sub-cutaneous, intra-muscular or nasal route, they allow to inhibit the gonadal functions in some hormone-dependent cancers and in true precocious puberty. More recently, they have been tested for the treatment of gonadotropic adenomas, where they may have sometimes a paradoxical effect. In combination with exogenous gonadotropins, they enhance the control of ovulation and are new valuable tools for IVF programs. Clinical studies with the LH-RH antagonists are just beginning. The long-acting bromocriptine affords a new alternative to the oral treatment of hyperprolactinaemia. Its suppressive effects lasts at least 35 days in normal subjects and 21 days in patients with macroprolactinomas.

37. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study

Author

Peeters, Stijn A., Engelen, Lian, Buijs, Jacqueline, Chaturvedi, Nish, Fuller, John H., Schalkwijk, Casper G., Stehouwer, Coen D, Karamanos, B., Kofinis, A., Petrou, K., Giorgino, F., Picca, G., Angarano, A., Null, de P. e. r. g. o. l. a. G., Laviola, L., Giorgino, R., Ionescu Tirgoviste, C., Coszma, A., Guja, C., Songini, M., Casu, A., Pedron, M., Pintus, S., Fossarello, M., Ferriss, J. B., Grealy, G., O'Keefe, D., Toeller, M., Arden, C., Rottiers, R., Tuyttens, C., Priem, H., Ebeling, P., Kylliainen, M., Koivisto, V. A., Idzior Walus, B., Sieradzki, J., Cyganek, K., Solnica, B., Lemkes, H. H. P. J., Lemkes Stuffken, J. C., Nunes Correa, J., Rogado, M. C., Gardete Correia, L., Cardoso, M. C., Silva, A., Boavida, J., Machado Sa Marques, M., Michel, G., Wirion, R., Cardillo, S., Pozza, G., Mangili, R., Asnaghi, V., Standl, E., Schaffler, B., Brand, H., Harms, A., Ben Soussan, M., Verier Mine, O., Fallas, P., Fallas, M. C., Fuller, J. H., Holloway, J., Asbury, L., Betteridge, D. J., Cathelineau, G., Bouallouche, A., Villatte Cathelineau, B., Santeusanio, F., Rosi, G., D'Alessandro, V., Cagini, C., Bottini, P., Reboldi, G. P., Navalesi, R., Penno, Giuseppe, Bandinelli, S., Miccoli, Roberto, Nannipieri, Monica, Ghirlanda, G., Saponara, C., Cotroneo, P., Manto, A., Minnella, A., Ward, J. D., Tesfaye, S., Eaton, S., Mody, C., Borra, M., Cavallo Perin, P., Giunti, S., Grassi, G., Pagano, G. F., Porta, M., Sivieri, R., Vitelli, F., Veglio, M., Papazoglou, N., Manes, G., Muggeo, M., Iagulli, M., Cacciatori, V., Cattedra di Malattie del Metabolismo, V., Irsigler, K., Abrahamian, H., Walford, S., Sinclair, J., Hughes, S., Mclelland, V., Ward, J., Roglic, G., Metelko, Z., Pepeonik, Z. R., Clinicum, Department of Medicine, Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), and RS: CARIM - R3 - Vascular biology

Subjects
Male, Endocrinology, Diabetes and Metabolism, Matrix metalloproteinase, Gastroenterology, Cohort Studies, Endocrinology, Prospective Studies, Endothelial dysfunction, Original Investigation, Settore MED/30 - MALATTIE APPARATO VISIVO, Middle Aged, Cardiovascular disease, 3. Good health, Europe, Diabetes and Metabolism, Albuminuria, Retinopathy, Tissue inhibitor of metalloproteinase, Type 1 diabetes, Adult, Biomarkers, Cross-Sectional Studies, Diabetes Complications, Diabetes Mellitus, Type 1, Female, Humans, Matrix Metalloproteinase 10, Matrix Metalloproteinase 2, Matrix Metalloproteinase 3, Tissue Inhibitor of Metalloproteinase-1, Vascular Diseases, Cardiology and Cardiovascular Medicine, medicine.symptom, Type 1, medicine.medical_specialty, education, Inflammation, Diabetes mellitus, Internal medicine, medicine, Diabetes Mellitus, business.industry, Settore MED/09 - MEDICINA INTERNA, medicine.disease, 3121 General medicine, internal medicine and other clinical medicine, business
Abstract

Background Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, −2, −3, −9, −10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, −2, −3, −9, −10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes. Electronic supplementary material The online version of this article (doi:10.1186/s12933-015-0195-2) contains supplementary material, which is available to authorized users.

Full Text
View/download PDF

38. Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study.

Author

Munch M, Meyer L, Hannedouche T, Kunz K, Alenabi F, Winiszewski P, Baltzinger P, Smagala A, Klein A, Dorey F, Fleury D, Verier-Mine O, Guerci B, Cridlig J, Borot S, Ducloux D, Meyer N, Hadjadj S, Chantrel F, and Kessler L

Subjects
Aged, Blood Glucose, Blood Glucose Self-Monitoring, Glycated Hemoglobin analysis, Humans, Middle Aged, Nitriles adverse effects, Prospective Studies, Pyrrolidines, Adamantane adverse effects, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Renal Dialysis, Vildagliptin therapeutic use
Abstract

Aim: To evaluate the effect of adding the dipeptidyl-peptidase-4 inhibitor vildagliptin to insulin on the glycaemic control of patients with type 2 diabetes undergoing haemodialysis., Methods: Overall, 65 insulin-treated patients with type 2 diabetes undergoing haemodialysis (HbA1c: 7.3% ± 1.1%; age: 70.5 ± 8.5 years) were randomized (1:1) either to receive vildagliptin 50 mg/day in addition to insulin (vildagliptin-insulin group) or to pursue their usual insulin regimen (insulin-only group). Continuous glucose monitoring (CGM) was performed for 48 ± 6 hours at baseline and at week 12. The primary study endpoint was change from baseline in mean interstitial glucose using CGM. The secondary endpoints included other CGM variables and glucose control markers., Results: After 12 weeks, a greater reduction in mean CGM glucose from baseline was observed in the vildagliptin-insulin group compared with the insulin-only group, although the between-treatment difference was not statistically significant (mean difference [CI 95%]: -0.96 mmol/L [-2.09; 0.18] vs. -0.29 mmol/L [-1.29; 0.76], P = 0.32). However, a significant decrease from baseline in HbA1c, glycated albumin and insulin daily doses was observed in the vildagliptin-insulin group versus the insulin-only group (-0.6% [-1.19; -0.1], P < 0.01), in the vildagliptin-insulin group versus no change in the insulin-only group (-130.6 μmol/L [-271; 10.7] vs. +36.2 μmol/L [-164.4; 236.9], P = 0.04 and - 5.9 IU/day [-1.8; 7.1] vs. +1.1 IU/day [-14.5; 16.6], P = 0.01, respectively). There was no significant difference in the percentage of time spent in hypoglycaemia using CGM, occurrence of severe hypoglycaemia or number of adverse events., Conclusion: In this study, vildagliptin added to insulin improved glycaemic control with an associated insulin-sparing effect in patients with type 2 diabetes undergoing haemodialysis and was well tolerated., (© 2020 John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

39. The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients.

Author

Marcos S, Sarfati J, Leroy C, Fouveaut C, Parent P, Metz C, Wolczynski S, Gérard M, Bieth E, Kurtz F, Verier-Mine O, Perrin L, Archambeaud F, Cabrol S, Rodien P, Hove H, Prescott T, Lacombe D, Christin-Maitre S, Touraine P, Hieronimus S, Dewailly D, Young J, Pugeat M, Hardelin JP, and Dodé C

Subjects
Adolescent, Adult, Child, Child, Preschool, Family Health, Female, Frameshift Mutation, Genotype, Heterozygote, Humans, Male, Middle Aged, Mutation, Missense, Pedigree, Phenotype, Prevalence, Young Adult, CHARGE Syndrome epidemiology, CHARGE Syndrome genetics, DNA Helicases genetics, DNA-Binding Proteins genetics, Kallmann Syndrome epidemiology, Kallmann Syndrome genetics
Abstract

Context: Mutations in CHD7, a gene previously implicated in CHARGE (coloboma, heart defect, choanal atresia, retardation of growth and/or development, genital hypoplasia, ear anomalies) syndrome, have been reported in patients presenting with Kallmann syndrome (KS) or congenital hypogonadotropic hypogonadism (CHH). Most mutations causing CHARGE syndrome result in premature stop codons and occur de novo, but the proportion of truncating vs nontruncating mutations in KS and CHH patients is still unknown., Objective: The objective of the study was to determine the nature, prevalence, mode of transmission, and clinical spectrum of CHD7 mutations in a large series of patients., Design: We studied 209 KS and 94 CHH patients. These patients had not been diagnosed with CHARGE syndrome according to the current criteria. We searched for mutations in 16 KS and CHH genes including CHD7., Results: We found presumably pathogenic mutations in CHD7 in 24 KS patients but not in CHH patients. Nontruncating mutations (16 missense and a two-codon duplication) were more prevalent than truncating mutations (three nonsense, three frame shift, and a splice site), which contrasts with patients presenting with typical CHARGE syndrome. Thus, the clinical spectrum associated with CHD7 mutations may be partly explained by genotype/phenotype correlations. Eight patients also had congenital deafness and one had a cleft lip/palate, whereas six had both. For 10 patients, the presence of diverse features of the CHARGE spectrum in at least one relative argues against a de novo appearance of the missense mutation, and this was confirmed by genetic analysis in five families., Conclusion: Considering the large prevalence and clinical spectrum of CHD7 mutations, it will be particularly relevant to genetic counseling to search for mutations in this gene in KS patients seeking fertility treatment, especially if KS is associated with deafness and cleft lip/palate.

Published
2014
Full Text
View/download PDF

40. Treating diabetes with islet transplantation: lessons from the past decade in Lille.

Author

Vantyghem MC, Defrance F, Quintin D, Leroy C, Raverdi V, Prévost G, Caiazzo R, Kerr-Conte J, Glowacki F, Hazzan M, Noel C, Pattou F, Diamenord AS, Bresson R, Bourdelle-Hego MF, Cazaubiel M, Cordonnier M, Delefosse D, Dorey F, Fayard A, Fermon C, Fontaine P, Gillot C, Haye S, Le Guillou AC, Karrouz W, Lemaire C, Lepeut M, Leroy R, Mycinski B, Parent E, Siame C, Sterkers A, Torres F, Verier-Mine O, Verlet E, Desailloud R, Dürrbach A, Godin M, Lalau JD, Lukas-Croisier C, Thervet E, Toupance O, Reznik Y, and Westeel PF

Subjects
C-Reactive Protein metabolism, Diabetes Mellitus, Type 1 immunology, Diabetes Mellitus, Type 1 physiopathology, Female, Humans, Insulin-Secreting Cells immunology, Male, Patient Selection, Practice Guidelines as Topic, Prognosis, Quality of Life, Reproducibility of Results, Risk Assessment, Treatment Outcome, Blood Glucose metabolism, Diabetes Mellitus, Type 1 surgery, Glycated Hemoglobin metabolism, Immunosuppressive Agents therapeutic use, Insulin-Secreting Cells metabolism, Islets of Langerhans Transplantation adverse effects, Islets of Langerhans Transplantation methods
Abstract

Type 1 diabetes (T1D) is due to the loss of both beta-cell insulin secretion and glucose sensing, leading to glucose variability and a lack of predictability, a daily issue for patients. Guidelines for the treatment of T1D have become stricter as results from the Diabetes Control and Complications Trial (DCCT) demonstrated the close relationship between microangiopathy and HbA1c levels. In this regard, glucometers, ambulatory continuous glucose monitoring, and subcutaneous and intraperitoneal pumps have been major developments in the management of glucose imbalance. Besides this technological approach, islet transplantation (IT) has emerged as an acceptable safe procedure with results that continue to improve. Research in the last decade of the 20th century focused on the feasibility of islet isolation and transplantation and, since 2000, the success and reproducibility of the Edmonton protocol have been proven, and the mid-term (5-year) benefit-risk ratio evaluated. Currently, a 5-year 50% rate of insulin independence can be expected, with stabilization of microangiopathy and macroangiopathy, but the possible side-effects of immunosuppressants, limited availability of islets and still limited duration of insulin independence restrict the procedure to cases of brittle diabetes in patients who are not overweight or have no associated insulin resistance. However, various prognostic factors have been identified that may extend islet graft survival and reduce the number of islet injections required; these include graft quality, autoimmunity, immunosuppressant regimen and non-specific inflammatory reactions. Finally, alternative injection sites and unlimited sources of islets are likely to make IT a routine procedure in the future., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)

Published
2014
Full Text
View/download PDF

41. French multicentric survey of outcome of pregnancy in women with pregestational diabetes.

Author

Boulot P, Chabbert-Buffet N, d'Ercole C, Floriot M, Fontaine P, Fournier A, Gillet JY, Gin H, Grandperret-Vauthier S, Geudj AM, Guionnet B, Hauguel-de-Mouzon S, Hieronimus S, Hoffet M, Jullien D, Lamotte MF, Lejeune V, Lepercq J, Lorenzi F, Mares P, Miton A, Penfornis A, Pfister B, Renard E, Rodier M, Roth P, Sery GA, Timsit J, Valat AS, Vambergue A, and Verier-Mine O

Subjects
Cross-Sectional Studies, Female, France epidemiology, Humans, Logistic Models, Pregnancy, Prevalence, Diabetes Mellitus, Type 1 epidemiology, Diabetes Mellitus, Type 2 epidemiology, Pregnancy Outcome epidemiology, Pregnancy in Diabetics epidemiology
Abstract

Objective: To evaluate perinatal outcome in pregnancies in women with type 1 and type 2 diabetes and the influence of preconception care 10 years after the St. Vincent's declaration., Research Design and Methods: A cross-sectional study was conducted in 12 perinatal centers in France in 2000-2001. The main investigated outcomes were perinatal mortality, major congenital malformations, and preterm delivery., Results: Among 435 single pregnancies, 289 (66.4%) were from women with type 1 and 146 (33.6%) from women with type 2 diabetes. Perinatal mortality rate was 4.4% (0.7% national rate), severe congenital malformations rate was 4.1% (2.2% national rate), and preterm delivery rate was 38.2% (4.7% national rate). Preconception care was provided in 48.5% women with type 1 diabetes and in 24.0% women with type 2 diabetes. Women whose first trimester HbA(1c) was >8% had higher rates of perinatal mortality (9.2 vs. 2.5%; odds ratio 3.9; 95% CI 1.5-9.7; P < 0.005), major congenital malformations (8.3 vs. 2.5%; 3.5; 1.3-8.9; P < 0.01), and preterm delivery (57.6 vs. 24.8%; 1.4; 1.1-1.7; P < 0.005) than those with first trimester HbA(1c) <8%. These results are similar to those reported in France in 1986-1988., Conclusions: Pregnancies in women with diabetes are still poorly planned and complicated by higher rates of perinatal mortality and major congenital malformations. Despite knowledge of the importance of intensified glycemic control before pregnancy, reaching the St. Vincent's target needs further implementation in France.

Published
2003
Full Text
View/download PDF

44. [Selective control of different hypophysial secretions by long-lasting pharmacodynamic agents. Analogs of somatostatin and LHRH and long-lasting bromocriptine].

Author

Fossati P, Dewailly D, and Verier-Mine O

Subjects
Gonadotropin-Releasing Hormone antagonists & inhibitors, Humans, Prolactin metabolism, Secretory Rate drug effects, Structure-Activity Relationship, Bromocriptine administration & dosage, Gonadotropin-Releasing Hormone analogs & derivatives, Somatostatin analogs & derivatives
Abstract

The biological activity of the natural somatostatin can be quantitatively and qualitatively altered by the substitution and/or the exclusion of some of its amino-acids. The most used synthetic analog, SMS 201-995, has a potent inhibiting effect on GH secretion, but is less effective on insulin and glucagon secretions. It is mainly used in Endocrinology for the treatment of acromegaly. It is also useful for inhibiting the inappropriate TSH secretion from a thyrotroph adenoma. The LH-RH agonists ast essentially by desensitizing the gonadotroph from the endogenous LH-RH. By sub-cutaneous, intra-muscular or nasal route, they allow to inhibit the gonadal functions in some hormone-dependent cancers and in true precocious puberty. More recently, they have been tested for the treatment of gonadotropic adenomas, where they may have sometimes a paradoxical effect. In combination with exogenous gonadotropins, they enhance the control of ovulation and are new valuable tools for IVF programs. Clinical studies with the LH-RH antagonists are just beginning. The long-acting bromocriptine affords a new alternative to the oral treatment of hyperprolactinaemia. Its suppressive effects lasts at least 35 days in normal subjects and 21 days in patients with macroprolactinomas.

Published
1988

45. [A case of intrasellar arachnoid cyst].

Author

Verier Mine O, Salomez-Granier F, Buvat J, Christiaens JL, and Linquette M

Subjects
Adult, Cysts physiopathology, Diagnosis, Differential, Female, Humans, Meningitis diagnosis, Meningitis physiopathology, Radiography, Sella Turcica diagnostic imaging, Arachnoid, Cysts diagnosis
Published
1983

Catalog

Books, media, physical & digital resources
See catalog results